2026 Q2 - tulosraportti
57 päivää sitten
‧47 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 | - | - | ||
| 15 | - | - | ||
| 88 | - | - | ||
| 855 | - | - | ||
| 35 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 13.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 21.8. | ||
2026 Q1 - tulosraportti 13.5. | ||
2025 Q4 - tulosraportti 12.3. | ||
2025 Q3 - tulosraportti 14.11.2025 | ||
2025 Q2 - tulosraportti 22.8.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·17 t sittenTime to buy in or is it too late though I think it can hit 300 later on
@Rio_ & peterman Nothing is 100% certain, but there are several things that can help influence the share price in a positive direction. Small selection here: 1. Eurofarma's application to the Brazilian health authorities for marketing of BAVA's CHIKV VLP vaccine = Chikungunya continues to spread in Brazil and last year more than 500,000 cases of chikungunya globally, of which > 50% are related to Brazil. 2. PP revenue already DKR 2,400 secured via orders currently out of budget of DKR 2,500 in 2026 and continued strong development and inter alia DKR 800 Mio secured for 2027. 3. Strong and growing sales in Travel Health. 4. Solid capital structure. 5. Robust profitability. 6. Solid execution with inter alia new markets. 7. New CEO etc. One must therefore search thoroughly for "negative" statements in their press releases and financial reports. The only immediate one is a reduction in revenue of Vimkunya of a meager DKR 50 Mio. NB! Have BAVA myself and was a strong opponent of the offer made last autumn by private equity funds.
·12.10.and no they should not just run their bizz they should keep eyes and ears open for when something is for sale that they understand@Michael Jensen. It indicates that they are looking forward when we look at Cash Flow from investing; 2024: -1.871 and 2025: -2.485 - i.e., an "investment growth" of 32.82% (purchase of property, plant and equipment, intangible assets and financial assets). And their share buyback program probably plays a significant role in this growth. If BAVA sees a nice growth potential in the coming time, then a share buyback program can be quite a nice investment - they buy, for example, now at price 230 and sell in, for example, 2 years at price 325 or even better out in the future. Next, cash flow from operations has grown by 39.59% from year 2024 to 2025. All in all, exciting whether the trend continues in the upcoming financial report. No wonder those private equity funds tried to acquire BAVA last year.- ·12.10.bavarian has in my opinion a low share price because none of the lottery tickets yielded anything with large drops as a result, the business is fine on what is so I am keeping
·10.10.have only 50 shares and am starting to get Fomo. Bavarian will hit price 300, if they don't do stupid things within the next 6-12 mos. And by stupid things, I just mean, coming up with something new. They practically shouldn't do anything right now other than run their bizz
Cool! Thanks for the answer, though I just halved my position since I bought a lot on the dip around 175 and therefore wanted to take a little profit. Looking forward to following the stock going forward! Good day to you all :)
·8.10.Strong result from the travel vaccines Paul Chaplin finishes strong, despite quite a bit of criticism over time.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
57 päivää sitten
‧47 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·17 t sittenTime to buy in or is it too late though I think it can hit 300 later on@Rio_ & peterman Nothing is 100% certain, but there are several things that can help influence the share price in a positive direction. Small selection here: 1. Eurofarma's application to the Brazilian health authorities for marketing of BAVA's CHIKV VLP vaccine = Chikungunya continues to spread in Brazil and last year more than 500,000 cases of chikungunya globally, of which > 50% are related to Brazil. 2. PP revenue already DKR 2,400 secured via orders currently out of budget of DKR 2,500 in 2026 and continued strong development and inter alia DKR 800 Mio secured for 2027. 3. Strong and growing sales in Travel Health. 4. Solid capital structure. 5. Robust profitability. 6. Solid execution with inter alia new markets. 7. New CEO etc. One must therefore search thoroughly for "negative" statements in their press releases and financial reports. The only immediate one is a reduction in revenue of Vimkunya of a meager DKR 50 Mio. NB! Have BAVA myself and was a strong opponent of the offer made last autumn by private equity funds.
- ·12.10.and no they should not just run their bizz they should keep eyes and ears open for when something is for sale that they understand@Michael Jensen. It indicates that they are looking forward when we look at Cash Flow from investing; 2024: -1.871 and 2025: -2.485 - i.e., an "investment growth" of 32.82% (purchase of property, plant and equipment, intangible assets and financial assets). And their share buyback program probably plays a significant role in this growth. If BAVA sees a nice growth potential in the coming time, then a share buyback program can be quite a nice investment - they buy, for example, now at price 230 and sell in, for example, 2 years at price 325 or even better out in the future. Next, cash flow from operations has grown by 39.59% from year 2024 to 2025. All in all, exciting whether the trend continues in the upcoming financial report. No wonder those private equity funds tried to acquire BAVA last year.
- ·12.10.bavarian has in my opinion a low share price because none of the lottery tickets yielded anything with large drops as a result, the business is fine on what is so I am keeping
- ·10.10.have only 50 shares and am starting to get Fomo. Bavarian will hit price 300, if they don't do stupid things within the next 6-12 mos. And by stupid things, I just mean, coming up with something new. They practically shouldn't do anything right now other than run their bizzCool! Thanks for the answer, though I just halved my position since I bought a lot on the dip around 175 and therefore wanted to take a little profit. Looking forward to following the stock going forward! Good day to you all :)
- ·8.10.Strong result from the travel vaccines Paul Chaplin finishes strong, despite quite a bit of criticism over time.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 | - | - | ||
| 15 | - | - | ||
| 88 | - | - | ||
| 855 | - | - | ||
| 35 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 13.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 21.8. | ||
2026 Q1 - tulosraportti 13.5. | ||
2025 Q4 - tulosraportti 12.3. | ||
2025 Q3 - tulosraportti 14.11.2025 | ||
2025 Q2 - tulosraportti 22.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
57 päivää sitten
‧47 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 13.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 21.8. | ||
2026 Q1 - tulosraportti 13.5. | ||
2025 Q4 - tulosraportti 12.3. | ||
2025 Q3 - tulosraportti 14.11.2025 | ||
2025 Q2 - tulosraportti 22.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·17 t sittenTime to buy in or is it too late though I think it can hit 300 later on@Rio_ & peterman Nothing is 100% certain, but there are several things that can help influence the share price in a positive direction. Small selection here: 1. Eurofarma's application to the Brazilian health authorities for marketing of BAVA's CHIKV VLP vaccine = Chikungunya continues to spread in Brazil and last year more than 500,000 cases of chikungunya globally, of which > 50% are related to Brazil. 2. PP revenue already DKR 2,400 secured via orders currently out of budget of DKR 2,500 in 2026 and continued strong development and inter alia DKR 800 Mio secured for 2027. 3. Strong and growing sales in Travel Health. 4. Solid capital structure. 5. Robust profitability. 6. Solid execution with inter alia new markets. 7. New CEO etc. One must therefore search thoroughly for "negative" statements in their press releases and financial reports. The only immediate one is a reduction in revenue of Vimkunya of a meager DKR 50 Mio. NB! Have BAVA myself and was a strong opponent of the offer made last autumn by private equity funds.
- ·12.10.and no they should not just run their bizz they should keep eyes and ears open for when something is for sale that they understand@Michael Jensen. It indicates that they are looking forward when we look at Cash Flow from investing; 2024: -1.871 and 2025: -2.485 - i.e., an "investment growth" of 32.82% (purchase of property, plant and equipment, intangible assets and financial assets). And their share buyback program probably plays a significant role in this growth. If BAVA sees a nice growth potential in the coming time, then a share buyback program can be quite a nice investment - they buy, for example, now at price 230 and sell in, for example, 2 years at price 325 or even better out in the future. Next, cash flow from operations has grown by 39.59% from year 2024 to 2025. All in all, exciting whether the trend continues in the upcoming financial report. No wonder those private equity funds tried to acquire BAVA last year.
- ·12.10.bavarian has in my opinion a low share price because none of the lottery tickets yielded anything with large drops as a result, the business is fine on what is so I am keeping
- ·10.10.have only 50 shares and am starting to get Fomo. Bavarian will hit price 300, if they don't do stupid things within the next 6-12 mos. And by stupid things, I just mean, coming up with something new. They practically shouldn't do anything right now other than run their bizzCool! Thanks for the answer, though I just halved my position since I bought a lot on the dip around 175 and therefore wanted to take a little profit. Looking forward to following the stock going forward! Good day to you all :)
- ·8.10.Strong result from the travel vaccines Paul Chaplin finishes strong, despite quite a bit of criticism over time.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 | - | - | ||
| 15 | - | - | ||
| 88 | - | - | ||
| 855 | - | - | ||
| 35 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt